AR107965A2 - PIRIMIDINE DERIVATIVES - Google Patents
PIRIMIDINE DERIVATIVESInfo
- Publication number
- AR107965A2 AR107965A2 ARP170100728A ARP170100728A AR107965A2 AR 107965 A2 AR107965 A2 AR 107965A2 AR P170100728 A ARP170100728 A AR P170100728A AR P170100728 A ARP170100728 A AR P170100728A AR 107965 A2 AR107965 A2 AR 107965A2
- Authority
- AR
- Argentina
- Prior art keywords
- unsubstituted
- substituted
- alkoxy
- alkyl
- cycloalkyl
- Prior art date
Links
Abstract
Reivindicación 1: Un compuesto de formula (1) donde cada uno de R⁰, R¹, R² y R³ es independientemente hidrógeno, alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈ cicloalquilo C₃₋₈, cicloalquilo C₃₋₈ alquilo C₁₋₃, aril C₅₋₁₀-alquilo C₁₋₈, hidroxialquilo C₁₋₈, alcoxi C₁₋₈-alquilo C₁₋₈, aminoalquilo C₁₋₈, haloalquilo C₁₋₈, arilo C₅₋₁₀ no sustituido o sustituido, heterociclilo de 5 ó 6 miembros no sustituido o sustituido que comprende 1, 2 ó 3 heteroátomos seleccionados de N, O y S, hidroxi, alcoxi C₁₋₈, hidroxialcoxi C₁₋₈, alcoxi C₁₋₈-alcoxi C₁₋₈, haloalcoxi C₁₋₈, aril C₅₋₁₀-alcoxi C₁₋₆ no sustituido o sustituido, heterocicliloxi no sustituido o sustituido, o heterociclilalcoxi C₁₋₈ no sustituido o sustituido, amino no sustituido o sustituido, alquiltio C₁₋₈, alquilsulfinilo C₁₋₈, alquilsulfonilo C₁₋₈, arilsulfonilo C₅₋₁₀, halógeno, carboxi, alcoxicarbonilo C₁₋₈, carbamoilo no sustituido o sustituido, sulfamoilo no sustituido o sustituido ciano o nitro: o R⁰ y R¹, R¹ y R², y/o R² y R³ forman, junto con los átomos de carbono a los cuales están unidos, un anillo carbocíclico o heterocíclico de 5 ó 6 miembros que comprende 0, 1, 2 ó 3 heteroátomos seleccionados de N, O y S; R⁴ es hidrógeno o alquilo C₁₋₈; cada uno de R⁵ y R⁶ independientemente es hidrógeno, alquilo C₁₋₈, alcoxi C₁₋₈-alquilo C₁₋₈, haloalquilo C₁₋₈, alcoxi C₁₋₈, halógeno, carboxi, alcoxicarbonilo C₁₋₈, carbamoilo no sustituido o sustituido, ciano, o nitro; y cada uno de R⁷, R⁸, R⁹ y R¹⁰ independientemente es alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈-alquilo C₁₋₆, arilo C₅₋₁₀-alquilo C₁₋₈, hidroxialquilo C₁₋₈, alcoxi C₁₋₈-alquilo C₁₋₈, aminoalquilo C₁₋₈ haloalquilo C₁₋₈ arilo C₅₋₁₀ no sustituido o sustituido, heterociclilo de 5 ó 6 miembros no sustituido o sustituido que comprende 1, 2 ó 3 heteroátomos seleccionados de N, O y S, hidroxi, alcoxi C₁₋₈, hidroxialcoxi C₁₋₈, alcoxi C₁₋₈-alcoxi C₁₋₈, haloalcoxi C₁₋₈, arilo C₅₋₁₀-alcoxi C₁₋₈ no sustituido o sustituido, heterocicliloxi no sustituido o sustituido, o heterociclilalcoxi C₁₋₈ no sustituido o sustituido, amino no sustituido o sustituido, alquiltio C₁₋₈, alquilsulfinilo C₁₋₈, alquilsulfonilo C₁₋₈, arilsulfonilo C₅₋₁₀, halógeno, carboxi, alcoxicarbonilo C₁₋₈, carbamoilo no sustituido o sustituido, sulfamoilo no sustituido o sustituido, ciano o nitro; donde R⁷, R⁸ y R⁹ independientemente entre sí también pueden ser hidrógeno; o R⁷ y R⁸, R⁸ y R⁹ y/o R⁹ y R¹⁰ forman junto con los átomos de carbono a los cuales están unidos, un anillo carbocíclico o heterocíclico de 5 ó 6 miembros que comprende 0, 1, 2 ó 3 heteroátomos seleccionados de N, O y S; A es C o N; y sus sales.Claim 1: A compound of formula (1) wherein each of R⁰, R¹, R² and R³ is independently hydrogen, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl C₃₋₈ cycloalkyl, C₃₋₈ cycloalkyl C₁ alkyl ₋₃, C₅₋₁₀-Cil-C alquilo alkyl, C hidro hydroxyalkyl, C₁₋₈ alkoxy-C₁₋₈ alkyl, C₁₋₈ aminoalkyl, C₁₋₈ haloalkyl, unsubstituted or substituted C₅₋₁₀ aryl, 5-heterocyclyl or 6 unsubstituted or substituted members comprising 1, 2 or 3 heteroatoms selected from N, O and S, hydroxy, C₁₋₈ alkoxy, C₁₋₈ hydroxyalkoxy, C₁₋₈ alkoxy-C₁₋₈ alkoxy, C₁₋₈ haloalkoxy, unsubstituted or substituted Cil-C₅₋₁₀-alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted C o heterocyclylalkoxy, unsubstituted or substituted amino, C₁₋₈ alkylthio, C₁₋₈ alkylsulfinyl, C₁₋₈ alkylsulfonyl , Cils arylsulfonyl , halogen, carboxy, C₁₋₈ alkoxycarbonyl, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl cyano or nitro: or R⁰ and R¹, R¹ and R², and / or R² and R³ form, together with the carbon atoms at which are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S; R⁴ is hydrogen or C₁₋₈ alkyl; each of R⁵ and R⁶ independently is hydrogen, C₁₋₈ alkyl, C₁₋₈ alkoxy-C alquilo alkyl, C₁₋₈ haloalkyl, C₁₋₈ alkoxy, halogen, carboxy, C₁₋₈ alkoxycarbonyl, unsubstituted or substituted carbamoyl, cyano, or nitro; and each of R⁷, R⁸, R⁹ and R¹⁰ independently is C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkyl-C₁₋₆ alkyl, C₅₋₁₀ aryl-C alquilo alkyl ₋₈, C₁₋₈ hydroxyalkyl, C₁₋₈ alkoxy-C alco alkyl, C amino aminoalkyl C₁₋₈ haloalkyl unsubstituted or substituted, unsubstituted or substituted 5- or 6-membered heterocyclyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, hydroxy, C₁₋₈ alkoxy, C₁₋₈ hydroxyalkoxy, C₁₋₈-C alco alkoxy, C₁₋₈ haloalkoxy, unsubstituted C₅₋₁₀-C₅₋₁₀ alkoxy or substituted, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted Cc heterocyclylalkoxy, unsubstituted or substituted amino, Cilt alkylthio, C₁₋₈ alkylsulfinyl, C₁₋₈ alkylsulfonyl, C₅₋₁₀ arylsulfonyl, halogen, carboxy, C₁ alkoxycarbonyl ₋₈, carbamo unsubstituted or substituted yl, unsubstituted or substituted sulfamoyl, cyano or nitro; where R⁷, R⁸ and R⁹ independently of one another can also be hydrogen; or R⁷ and R⁸, R⁸ and R⁹ and / or R⁹ and R¹⁰ together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N , O and S; A is C or N; And its salts.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0319227A GB0319227D0 (en) | 2003-08-15 | 2003-08-15 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107965A2 true AR107965A2 (en) | 2018-07-04 |
Family
ID=28052593
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100728A AR107965A2 (en) | 2003-08-15 | 2017-03-23 | PIRIMIDINE DERIVATIVES |
| ARP190100267A AR114354A2 (en) | 2003-08-15 | 2019-02-04 | PYRIMIDINE DERIVATIVES |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100267A AR114354A2 (en) | 2003-08-15 | 2019-02-04 | PYRIMIDINE DERIVATIVES |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1832929B (en) |
| AR (2) | AR107965A2 (en) |
| GB (1) | GB0319227D0 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2091918E (en) * | 2006-12-08 | 2014-11-24 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| BRPI1012140A2 (en) * | 2009-05-15 | 2016-05-03 | Insight Genetics Inc | methods and compositions related to alkaline fusions for cancer diagnosis and treatment |
| EP2917210B1 (en) * | 2012-11-06 | 2019-02-27 | Shanghai Fochon Pharmaceutical Co. Ltd | Alk kinase inhibitors |
| ES2738493T3 (en) * | 2013-03-14 | 2020-01-23 | Tolero Pharmaceuticals Inc | JAK2 and ALK2 inhibitors and methods for their use |
| CN104628657A (en) * | 2013-11-06 | 2015-05-20 | 韩冰 | Class of compounds for treating ischemic brain damage and purpose thereof |
| CN104926794B (en) * | 2014-03-17 | 2017-12-05 | 广东东阳光药业有限公司 | Substituted heteroaryl compound and combinations thereof and purposes |
| CN106008503B (en) * | 2015-03-31 | 2020-09-01 | 齐鲁制药有限公司 | Spirocyclic aryl sulfones as protein kinase inhibitors |
| CN106146525B (en) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | Three and ring class anaplastic lymphoma kinase inhibitor |
| CN106187915A (en) * | 2015-05-27 | 2016-12-07 | 上海翰森生物医药科技有限公司 | There is inhibitor of ALK Yu EGFR double activity and its preparation method and application |
| CN106349224A (en) * | 2016-08-03 | 2017-01-25 | 山东大学 | JAK kinase inhibitor with 4-amino-(1H)-pyrazole structure and preparation method and application thereof |
| CN110092759A (en) * | 2018-01-31 | 2019-08-06 | 陆柯潮 | The chloro- 2,4- pyrimidine derivatives of 5- as anti-tumor drug |
| CN114716385B (en) * | 2022-04-08 | 2024-03-12 | 北京师范大学 | Compound of targeted focal adhesion kinase, preparation method and application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
-
2003
- 2003-08-15 GB GB0319227A patent/GB0319227D0/en not_active Ceased
-
2004
- 2004-08-13 CN CN2004800227255A patent/CN1832929B/en active Active
-
2017
- 2017-03-23 AR ARP170100728A patent/AR107965A2/en unknown
-
2019
- 2019-02-04 AR ARP190100267A patent/AR114354A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR114354A2 (en) | 2020-08-26 |
| CN1832929B (en) | 2012-11-07 |
| GB0319227D0 (en) | 2003-09-17 |
| CN1832929A (en) | 2006-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107965A2 (en) | PIRIMIDINE DERIVATIVES | |
| AR045458A1 (en) | PIRIMIDINE DERIVATIVES | |
| AR107966A2 (en) | INHIBITING PYRIMIDINE AND PYRIDINE DERIVATIVES OF THE QUINASA PROTEIN | |
| AR111279A1 (en) | USEFUL HETEROCYCLIC DERIVATIVES AS DUAL INHIBITORS OF ATX / CA | |
| AR114254A1 (en) | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS, PHARMACEUTICAL COMPOSITIONS, TREATMENT METHODS AND PREPARATION PROCESS OF MODULATORS | |
| AR127309A2 (en) | PYRDAZINONE DERIVATIVES | |
| AR112529A1 (en) | DERIVATIVES OF 3- (1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME IN THE TREATMENT OF VARIOUS TYPES OF CANCER | |
| CO6251260A2 (en) | BIFENYLL DERIVATIVES CONFORMALLY RESTRICTED FOR USE AS INHIBITORS OF THE HEPATITIS VIRUS C. | |
| AR066669A1 (en) | IMIDAZOLONA DERIVATIVES AS INHIBITORS OF BENCIMIDAZOLONA QUIMASA. PHARMACEUTICAL COMPOSITIONS. | |
| AR060651A1 (en) | DERIVATIVES OF 1,2,4-TRIAZOL AS MODULATORS OF MGLUR5 I, INTERMEDIARIES FOR SYNTHESIS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF PAIN AND GASTROINTESTINAL DISORDERS | |
| AR011776A1 (en) | A PHARMACEUTICAL ACCOMPOSITION TO TREAT DISORDERS OF APPETITION FOR THE CONSUMPTION OF CARBOHYDRATES OR ALCOHOLS | |
| AR099498A1 (en) | TRIAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | |
| AR070463A1 (en) | AMINA AND ETER COMPOUNDS THAT MODULATE THE CB2 RECEIVER | |
| CO5700764A2 (en) | DIHYDROQUINAZOLINS REPLACED WITH ANTIVIRAL PROPERTIES | |
| AR046083A1 (en) | DERIVATIVES OF 2 PIRIDONA AS INHIBITORS OF THE ELASTASA DE NEUTROFILOS | |
| PE20080830A1 (en) | SULFONYL-DERIVED COMPOUNDS THAT MODULATE THE CB2 RECEPTOR | |
| CO5640117A2 (en) | 2,4-DIAMONOPIRIMIDINE DERIVATIVES | |
| AR104208A1 (en) | BICYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS (ATX) | |
| CO4950625A1 (en) | NICOTINAMIDE DERIVATIVES | |
| AR005277A1 (en) | DERIVATIVES OF PIPERIDINE 1- (PIPERIDINIL 1,2 DISSTITUTED) -4-SUBSTITUTED, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION THAT CONTAIN THEM, PROCESS TO PREPARE SUCH COMPOSITIONS AND USE OF SUCH DERIVATIVES AS MEDICINES. | |
| CO6270328A2 (en) | PIRROLO DERIVATIVES [2,3] PYRIMIDINE AS INHIBITORS OF KINASE PROTEINS B | |
| BRPI0519288A2 (en) | heterocyclic compounds as ccr2b antagonists | |
| PE20110397A1 (en) | COMPOUNDS THAT SELECTIVELY MODULATE THE CB2 RECEIVER | |
| AR096846A1 (en) | DIHYDROCHINOXALINONES AND MODIFIED DIHYDROPIRIDOPIRAZINONES AS INHIBITORS OF BET PROTEIN | |
| PE20181304A1 (en) | INDEOL N-SUBSTITUTE DERIVATIVES AS MODULATORS OF PGE2 RECEPTORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |